Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Checkmate Pharmaceuticals Inc.

Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired

BioCentury | Nov 5, 2024
Management Tracks

Alan Bash named president of Carvykti at Legend

Plus: CureVac hires Axel Malkomes as CFO; new CEOs at Coya, Libra; and updates from 4BIO, Memo and Alltrna
BioCentury | Jun 19, 2024
Management Tracks

Seaport adds Loebel as CMO, Gladstein as general counsel

Plus: SpyBiotech names Keith Dewedoff CFO, and updates from Kriya, CytomX and Progentec
BioCentury | Mar 12, 2024
Management Tracks

Hyku names Kleem Chaudhary CEO

Plus: Jones hired as CBO at MOMA, and updates from Metrion, OPPI, 4BIO and Quotient
BioCentury | Dec 5, 2023
Management Tracks

Glucksmann at the helm at Sensorium

Plus: CEO, CMO out at Theseus and updates from Zenas, Nanoscope, Immunitas and more
BioCentury | Jan 4, 2023
Management Tracks

Ex-Checkmate CEO Bash to lead ZielBio

Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more
BioCentury | Nov 3, 2022
Management Tracks

Fantaccini becomes head of medical affairs, CSO at Novartis

Plus Maraganore named chair at GNS, and updates from Cardior, Protagonist and Tyra
BioCentury | Jun 2, 2022
Deals

Seeking more control over combos, Regeneron retakes full rights to cancer ‘backbone’ Libtayo

Biotech buys out Sanofi’s share of profits from PD-1 inhibitor, sees drug as ‘centerpiece’ in oncology growth
BioCentury | Apr 19, 2022
Deals

Regeneron makes closing move on Checkmate, gaining cancer program in $250M deal

Regeneron adds partner Checkmate’s clinical TLR9 program via high-premium takeout, with stock near all-time low
BioCentury | Oct 28, 2021
Management Tracks

Labinger out as Checkmate CEO

Plus: Travecta, MTS Health Partners, Elevar and Y Combinator
BioCentury | Sep 3, 2021
Management Tracks

Civetta picks Roberts as CEO

Plus, management moves at Crinetics, OraSure, Silence, Avacta, Oncternal and more
Items per page:
1 - 10 of 40